# Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April–1 May 2015, Athens

**Authors:** Andreas Leithner, Dimosthenis Andreou, Robert Grimer, Stefano Ferrari, Georg Gosheger, Panayiotis J Papagelopoulos, Stefan S Bielack

PMC · DOI: 10.3332/ecancer.2015.550 · ecancermedicalscience · 2015-07-08

## TL;DR

This report summarizes the 28th annual meeting of a European society focused on bone and soft tissue sarcomas, highlighting recent advances in diagnosis and treatment.

## Contribution

The paper provides a summary of recent interdisciplinary advancements in sarcoma research and treatment strategies discussed at the meeting.

## Key findings

- The meeting emphasized recent advances in the diagnosis of bone and soft tissue sarcomas.
- New treatment strategies were discussed by an interdisciplinary group of experts.
- The interdisciplinary collaboration was highlighted as a key strength of the meeting.

## Abstract

The 28th Annual Meeting of the European Musculo-Skeletal Oncology Society was organised in Athens by the local host Professor Papagelopoulos and his team. The main objective of the meeting was to focus on recent advances in the diagnosis and treatment of bone and soft tissue sarcomas. The interdisciplinary nature of the meeting was of great value—surgeons, oncologists, pathologists, radiologists, and basic researchers discussed new strategies in the war on sarcoma. This report will highlight the major findings of this successful meeting.

## Full-text entities

- **Genes:** FLT4 (fms related receptor tyrosine kinase 4) [NCBI Gene 2324] {aka CHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL}, TFE3 (transcription factor binding to IGHM enhancer 3) [NCBI Gene 7030] {aka MRXSPF, RCCP2, RCCX1, TFEA, bHLHe33}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, MCAM (melanoma cell adhesion molecule) [NCBI Gene 4162] {aka CD146, HEMCAM, METCAM, MUC18, MelCAM}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, ASPSCR1 (ASPSCR1 tether for SLC2A4, UBX domain containing) [NCBI Gene 79058] {aka ASPCR1, ASPL, ASPS, RCC17, TUG, UBXD9}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}
- **Diseases:** ill (MESH:D002908), undifferentiated pleomorphic sarcoma (MESH:D002277), aneurysmal bone cysts (MESH:D017824), pulmonary implants (MESH:D057873), giant cell tumours (MESH:D018286), Sarcoma (MESH:D012509), blood loss (MESH:D016063), giant cell tumour of bone (MESH:D018212), febrile neutropenia (MESH:D064147), ASPS (MESH:D018234), bone and soft tissue tumour (MESH:D012983), metastases (MESH:D009362), infected (MESH:D007239), bleeding (MESH:D006470), oncology (MESH:D000072716), bone cancer (MESH:D001859), disease (MESH:D004194), renal and peripheral neurotoxicity (MESH:D058729), fracture (MESH:D050723), clear cell sarcoma (MESH:D018227), renal toxicity (MESH:D007674), extraskeletal myxoid chondrosarcoma (MESH:C563195), bone defects (MESH:D001847), chordomas (MESH:D002817), dislocation (MESH:D004204), Pelvic and sacral tumours (MESH:D010386), Tumour Surgery (MESH:D009369), Osteosarcoma (MESH:D012516), hypotensive (MESH:D007022), metastatic disease (MESH:D000092182), toxicity (MESH:D064420), Ewing sarcomas (MESH:D012512), multiple myeloma (MESH:D009101)
- **Chemicals:** cediranib (MESH:C500926), sunitinib (MESH:D000077210), Mifamurtide (MESH:C037144), Denosumab (MESH:D000069448), APG880 (-), crizotinib (MESH:D000077547), alcohol (MESH:D000438)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4531125/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC4531125/full.md

---
Source: https://tomesphere.com/paper/PMC4531125